|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||5.10 - 5.40|
|52-week range||4.98 - 8.56|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||11.00|
GOSSELIES, Belgium, January 25, 2022--Regulatory News: TheraVet (Paris:ALVET) (Brussels:ALVET) (ISIN: BE0974387194 - ticker: ALVET), a pioneering biotechnology company specialising in the management of osteoarticular diseases in pets, presents its half-year operational update ending December 31, 2021.
GOSSELIES, Belgium, January 18, 2022--Regulatory News: TheraVet (Paris:ALVET) (Brussels:ALVET) (ISIN: BE0974387194 - ticker: ALVET), a biotech company developing pioneering treatments for osteoarticular disease in pets, announced today the signature of a non-exclusive commercial distribution agreement for its BIOCERA-VET® bone substitute in France with the veterinary co-operative Centravet, one of France’s leading wholesaler/distributors of animal health products. The agreement covers the BIOCER
GOSSELIES, Belgique, January 10, 2022--Regulatory News: TheraVet (code ISIN: BE0974387194 - mnémonique: ALVET) (Paris:ALVET) (Brussels:ALVET), a pioneering company in the management of osteoarticular diseases in companion animals, announces today the initiation of commissioned research coverage of its title by Degroof Petercam, with a study entitled "Revolutionizing the treatment of osteoarticular diseases".